Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Sales | 0 | 7,636,126 | 0 | 0 | 7,731,136 |
| Cost of Goods | N/A | 2,654,258 | N/A | N/A | 2,476,506 |
| Gross Profit | N/A | 4,981,868 | N/A | N/A | 5,254,630 |
| Operating Expenses | 0 | 3,708,628 | 0 | 0 | 4,190,637 |
| Operating Income | N/A | 1,273,505 | N/A | N/A | 1,064,506 |
| Interest Expense | 0 | 739,390 | 0 | 0 | 382,022 |
| Other Income | 0 | 505,232 | 0 | 0 | 191,782 |
| Pre-tax Income | 0 | 1,039,347 | 0 | 0 | 874,266 |
| Income Tax | N/A | 181,822 | N/A | N/A | 264,346 |
| Net Income Continuous | N/A | 857,525 | N/A | N/A | 609,920 |
| Minority Interests | N/A | 248 | N/A | N/A | 326 |
| Net Income | $N/A | $857,277 | $N/A | $N/A | $609,587 |
| EPS Basic Total Ops | N/A | 0.27 | N/A | N/A | 0.19 |
| EPS Basic Continuous Ops | N/A | 0.27 | N/A | N/A | 0.19 |
| EPS Diluted Total Ops | N/A | 0.27 | N/A | N/A | 0.19 |
| EPS Diluted Continuous Ops | N/A | 0.27 | N/A | N/A | 0.19 |
| EPS Diluted Before Non-Recurring Items | 0.44 | 0.52 | 0.42 | 0.44 | 0.56 |
| EBITDA(a) | $N/A | $2,526,787 | $N/A | $N/A | $2,294,708 |